Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 3
2005 1
2006 5
2007 2
2008 2
2009 2
2010 2
2011 8
2012 5
2013 6
2014 4
2015 6
2016 4
2017 6
2018 4
2019 8
2020 4
2021 8
2022 18
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, Guille A, Carbuccia N, Farina A, Agavnian E, Chaffanet M, Gonçalves A, Charafe-Jauffret E, Mamessier E, Birnbaum D, Bertucci F, Lopez M. Cabaud O, et al. Among authors: mamessier e. Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013. Mol Cancer Ther. 2022. PMID: 35534238
Sacituzumab govitecan in triple-negative breast cancer.
de Nonneville A, Goncalves A, Mamessier E, Bertucci F. de Nonneville A, et al. Among authors: mamessier e. Ann Transl Med. 2022 Jun;10(11):647. doi: 10.21037/atm-22-813. Ann Transl Med. 2022. PMID: 35813338 Free PMC article. No abstract available.
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Shigeta K, et al. Among authors: mamessier e. Hepatology. 2020 Apr;71(4):1247-1261. doi: 10.1002/hep.30889. Epub 2019 Oct 14. Hepatology. 2020. PMID: 31378984 Free PMC article.
Loss of primary cilia promotes inflammation and carcinogenesis.
Paul C, Tang R, Longobardi C, Lattanzio R, Eguether T, Turali H, Bremond J, Maurizy C, Gabola M, Poupeau S, Turtoi A, Denicolai E, Cufaro MC, Svrcek M, Seksik P, Castronovo V, Delvenne P, de Laurenzi V, Da Costa Q, Bertucci F, Lemmers B, Pieragostino D, Mamessier E, Janke C, Pinet V, Hahne M. Paul C, et al. Among authors: mamessier e. EMBO Rep. 2022 Dec 6;23(12):e55687. doi: 10.15252/embr.202255687. Epub 2022 Oct 25. EMBO Rep. 2022. PMID: 36281991 Free PMC article.
Mutational landscape of inflammatory breast cancer.
Bertucci F, Lerebours F, Ceccarelli M, Guille A, Syed N, Finetti P, Adélaïde J, Van Laere S, Goncalves A, Viens P, Birnbaum D, Mamessier E, Callens C, Bedognetti D. Bertucci F, et al. Among authors: mamessier e. J Transl Med. 2024 Apr 18;22(1):374. doi: 10.1186/s12967-024-05198-4. J Transl Med. 2024. PMID: 38637846 Free PMC article.
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
de Nonneville A, Finetti P, Mamessier E, Bertucci F. de Nonneville A, et al. Among authors: mamessier e. J Natl Cancer Inst. 2022 Jul 11;114(7):1046-1047. doi: 10.1093/jnci/djac031. J Natl Cancer Inst. 2022. PMID: 35148398 Free PMC article. No abstract available.
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, Lumet G, Ceccarelli M, Birnbaum D, Bedognetti D, Mamessier E, Barlesi F, Bertucci F, Tomasini P. Mogenet A, et al. Among authors: mamessier e. J Transl Med. 2023 Sep 19;21(1):637. doi: 10.1186/s12967-023-04463-2. J Transl Med. 2023. PMID: 37726776 Free PMC article.
102 results